Biofourmis, which uses medical wearables to test pharmaceutical drugs, raises $100M led by SoftBank's Vision Fund 2 with participation from Sequoia
Christina Farr / CNBC :
Context & Ripple Effects
This round extends a decade-long bet on software-driven medicine. Andreessen Horowitz set the template back in 2015 with its $200M health-software fund targeting computational medicine, and SoftBank's Vision Fund 2 has since made digital therapeutics a repeat position, backing Big Health's Sleepio and Daylight apps just months before this deal.
Biofourmis sits at the intersection of those two threads: using consumer-grade medical wearables not to treat patients but to generate clinical data for pharmaceutical drug testing. The category has since matured enough that dedicated sensor firms like VivoSense raised institutional money to serve the same clinical-trial market.
First-order effects
- Biofourmis gains $100M to scale its wearable-based drug-testing platform, with Sequoia's Alfred Lin and Pat Grady joining as new stewards alongside lead investor SoftBank Vision Fund 2.
- SoftBank doubles down on the digital-health thesis it already held through Big Health, while Sequoia deploys part of the roughly $10B in fresh funding it recently closed.
Second-order effects
- Pharma sponsors running trials with Biofourmis get a funded alternative to traditional site-based monitoring, pressuring contract research organizations and pushing wearable-sensor specialists like VivoSense to compete on the same trial-data workflows.
- The round sets a valuation benchmark for remote-monitoring platforms like Q Bio, which sells continuous health monitoring directly to consumers at $3,495/year and now faces a better-capitalized clinical counterpart.
Third-order effects
- If wearable-generated endpoints keep replacing episodic clinic visits, drug development consolidates around companies that own both the sensor layer and the data pipeline — the same structure later visible in AI biology efforts like Bioptimus and Network Bio building foundation models on pooled patient samples.
- Regulators and trial sponsors face growing pressure to accept continuous biometric data as primary evidence, reshaping how clinical evidence is generated and reviewed across the industry.
The trend: Clinical drug development is shifting from site-based measurement to continuous wearable-generated data, with mega-funds like SoftBank's Vision Fund 2 underwriting the platform layer.